Addex Therapeutics has announced a significant change in its executive management. The company has appointed Jean-Philippe Rocher as the new Head of Pharmaceutical Development. This change is crucial as Addex focuses on advancing its portfolio of innovative treatments for neurological disorders.
On October 2, 2026, the company revealed that Mikhail Kalinichev, who previously held the position of Head of Translational Science, has stepped down to dedicate his efforts to a similar role at Neurosterix.
Background
Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company based in Geneva, Switzerland. It specializes in developing novel small molecule allosteric modulators for neurological disorders. The company's shares are traded on the Nasdaq under the ticker ADXN. Addex operates within the pharmaceutical preparations sector, as classified under SIC 2834.
What the Filing Says
The recent filing includes a press release announcing the executive changes. It states, "Jean-Philippe Rocher has been appointed as Head of Pharmaceutical Development and member of the Executive Management." The release also mentions that Kalinichev has decided to step down to focus on his role at Neurosterix.
Impact
This management change may significantly impact Addex's direction and operational strategies. Rocher's extensive experience in drug discovery and development is expected to enhance the company's capabilities in advancing its clinical development plans. His prior roles at Addex and other prominent companies in the industry position him well to lead these efforts.
What's Next
The filing does not specify what happens next following these management changes.